PPARA and metabolic dysfunction-associated steatohepatitis: Elafibranor is a peroxisome proliferator–activated receptor alpha and delta (PPAR‐α/δ) regulate lipid metabolism in liver and glucose homeostasis.70 The GOLDEN‐505 study was a phase‐IIb, randomized, placebo‐controlled trial that included 274 patients with NASH and no cirrhosis who were randomized to either elafibranor 80 or 120 mg/d, or placebo, for 52 weeks.22 The primary endpoint, reversal of NASH without worsening of fibrosis was not met though the definitions in this trial were slightly different from comparable studies.